Summary & Overview
HCPCS G8633: Pharmacologic Therapy for Osteoporosis Prescribed
HCPCS Level II code G8633 identifies the prescription of pharmacologic therapy (excluding minerals and vitamins) for osteoporosis. Nationally, this code captures a key aspect of outpatient management for patients at risk of fractures and bone loss, reflecting the growing emphasis on medication-based prevention and treatment strategies for osteoporosis. Use of this code supports tracking of therapeutic initiation and adherence to pharmacologic interventions in outpatient care.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what the code represents, the typical service settings where it is used, and which major payers recognize this service. The publication outlines benchmarks and policy-relevant considerations for coding and billing pharmacologic osteoporosis therapy, summarizes clinical context around medication-based management, and highlights where data is not available in the input. This resource is intended for clinicians, billers, and policy analysts seeking a national-level understanding of HCPCS Level II code G8633.
Billing Code Overview
HCPCS Level II code G8633 denotes pharmacologic therapy (other than minerals/vitamins) for osteoporosis prescribed. This code represents services related to the prescription of non-mineral and non-vitamin medications used to treat osteoporosis.
-
Service type: Prescription management and medication therapy for osteoporosis
-
Typical site of service: Outpatient clinic, ambulatory care setting, or other outpatient prescription services
Data not available in the input for additional fields such as associated taxonomies, ICD-10 diagnoses, or related codes.
Clinical & Coding Specifications
Clinical Context
A 68-year-old postmenopausal woman with a history of low-trauma wrist fracture presents to her primary care clinic for osteoporosis management. Bone mineral density testing (DXA) demonstrates a T-score of -2.8 at the femoral neck, consistent with osteoporosis. After a shared discussion of risks and benefits, the clinician prescribes an antiresorptive pharmacologic agent (for example, an oral bisphosphonate or an intravenous bisphosphonate infusion, or subcutaneous denosumab). The prescription is documented in the medical record, including indication, informed consent discussion, baseline labs (serum calcium, renal function), and a treatment plan with monitoring intervals.
The clinical workflow includes: initial assessment with review of fracture history and DXA results, evaluation for secondary causes of bone loss and contraindications, laboratory screening, selection of an appropriate pharmacologic agent, documentation of the prescription and plan in the chart, patient education on administration and adverse effects, arrangement for infusion or injection if parenteral therapy is selected, and follow-up visits for adherence and tolerance. Billing uses HCPCS Level II code G8633 to indicate that pharmacologic therapy (other than minerals/vitamins) for osteoporosis has been prescribed, typically reported by outpatient clinics, infusion centers, and primary care or specialty practices managing osteoporosis.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 |